{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:48:01Z","timestamp":1791229681983,"version":"4.1.0"},"reference-count":21,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Bone and joint infections remain therapeutic challenges, usually requiring prolonged intravenous therapy and hospitalization. Dalbavancin, a long-acting lipoglycopeptide, offers a simplified alternative. We retrospectively analysed 83 patients treated with dalbavancin for osteomyelitis, spondylodiscitis, septic arthritis, or prosthetic joint infection in two tertiary Greek hospitals (2022\u20132024). Mean age was 69 \u00b1 16 years; 56.6% were male; Charlson Comorbidity Index averaged 4 \u00b1 2.25. Common comorbidities included diabetes (28.9%) and coronary artery disease (18.1%). Infections were vertebral osteomyelitis\/spondylodiscitis (48.2%), non-vertebral osteomyelitis (38.5%), prosthetic joint infection (10.8%), and septic arthritis (8.4%). Microbiological diagnosis was established in 62.6%; predominant pathogens were Staphylococcus aureus (38.4%: 30.7% MSSA, 7.7% MRSA) and enterococci (25%, including 5.7% VRE). Dalbavancin was administered as monotherapy (32.4%) or combined with other antibiotics (67.6%), mainly fluoroquinolones (63.6%) and minocycline (23.6%). Mean dosing was 2 \u00b1 2.36 administrations (4 \u00b1 4.38 g total). Surgical debridement was performed in 36.1% of patients. Clinically significant adverse events occurred in 4 patients (4.8%): acute kidney injury (n = 2), angioedema (n = 1), and Clostridioides difficile colitis (n = 1). Clinical cure was achieved in 90.4% at day 90 and 92.8% at day 180. Clinical cure rates were comparable between dalbavancin monotherapy and combination therapy, suggesting that the efficacy observed was primarily attributable to dalbavancin itself. Relapse at one year occurred in 10.8%, mainly due to inadequate source control. Dalbavancin demonstrated high efficacy, favourable safety, and treatment simplification in complex bone and joint infections. Its long half-life and reduced need for prolonged IV access support its role in minimizing hospitalization and catheter-related complications, particularly in regions with limited outpatient parenteral therapy infrastructure.<\/jats:p>","DOI":"10.3390\/pathogens14111109","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:15:14Z","timestamp":1762175714000},"page":"1109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Christina","family":"Petropoulou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1082-5674","authenticated-orcid":false,"given":"Petros","family":"Ioannou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Heraklion, 71110 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Eleftherakis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Papazisi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Heraklion, 71110 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Davoulos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Drosou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-8098","authenticated-orcid":false,"given":"Anastasia","family":"Spiliopoulou","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Tsiata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Paliogianni","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0255-5926","authenticated-orcid":false,"given":"Diamantis","family":"Kofteridis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Heraklion, 71110 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-2398","authenticated-orcid":false,"given":"Markos","family":"Marangos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-3681","authenticated-orcid":false,"given":"Stelios F.","family":"Assimakopoulos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00259-019-4262-x","article-title":"Consensus document for the diagnosis of peripheral bone infection in adults","volume":"46","author":"Glaudemans","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 IDSA Clinical Practice Guideline for Native Vertebral Osteomyelitis","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: Clinical practice guidelines","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Darlow, C.A., Parsons, J., Lucy, D., Li, A., Ratcliffe, L., Todd, S., and Wong, N. (2025). Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary setting. Infection.","DOI":"10.1007\/s15010-025-02585-x"},{"key":"ref_5","first-page":"20499361241245523","article-title":"Dalbavancin as an alternative to traditional OPAT for deep gram-positive infections","volume":"11","author":"Bao","year":"2024","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_6","first-page":"449","article-title":"The role of long-acting antibiotics in the clinical practice: A narrative review","volume":"31","author":"Micheli","year":"2023","journal-title":"Infez. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Somolinos, M., D\u00edaz-Navarro, M., Benjumea, A., Matas, J., Vaquero, J., Mu\u00f1oz, P., Sanz-Ru\u00edz, P., and Guembe, M. (2023). In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement. Antibiotics, 12.","DOI":"10.20944\/preprints202306.2198.v1"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dimopoulou, D., Mantadakis, E., Koutserimpas, C., and Samonis, G. (2023). A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. Antibiotics, 12.","DOI":"10.3390\/antibiotics12101492"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lovatti, S., Tiecco, G., Mul\u00e9, A., Rossi, L., Sforza, A., Salvi, M., Signorini, L., Castelli, F., and Quiros-Roldan, E. (2023). Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071005"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Parruti, G., Polilli, E., Coladonato, S., Rapacchiale, G., Trave, F., Mazzotta, E., Bondanese, M., Di Masi, F., Recinelli, D., and Corridoni, S. (2024). Safety and efficacy of dalbavancin in real life: Retrospective analysis of a large case series. Antibiotics, 13.","DOI":"10.3390\/antibiotics13111063"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged dalbavancin use in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","first-page":"1008","article-title":"Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of Gram-positive cocci","volume":"38","author":"Murray","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"ref_15","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2025, September 01). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 14.0. Available online: https:\/\/www.eucast.org\/clinical_breakpoints."},{"key":"ref_16","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2019). The \u201cI\u201d in EUCAST\u2014From \u201cIntermediate\u201d to \u201cSusceptible, Increased Exposure\u201d, EUCAST. Available online: https:\/\/www.eucast.org\/newsiandr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","article-title":"Effectiveness of Dalbavancin Compared with Standard of Care for Osteomyelitis: A Real-world Analysis","volume":"9","author":"Cain","year":"2021","journal-title":"Open Forum Infect Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102473","DOI":"10.1016\/j.jiac.2024.07.013","article-title":"Dalbavancin for the treatment of bone and joint infections: A meta-analysis","volume":"31","author":"Almangour","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_20","first-page":"60","article-title":"Dalbavancin treatment for spondylodiscitis: Multi-center clinical experience and literature review","volume":"34","author":"Ramadan","year":"2021","journal-title":"J. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lueking, R., Wei, W., Mang, N.S., Ortwine, J.K., and Meisner, J. (2023). Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.02385-22"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:07:17Z","timestamp":1762178837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pathogens14111109"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14111109","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}